Anti-HER3 monoclonal antibody patritumab sensitizes refractory non-small cell lung cancer to the epidermal growth factor receptor inhibitor erlotinib

Oncogene

Volumn 35, Issue 7, 2016, Pages 878-886

  Yonesaka, K ^a   Hirotani, K ^b   Kawakami, H ^a   Takeda, M ^a   Kaneda, H ^a   Sakai, K ^a   Okamoto, I ^c   Nishio, K ^a   Janne P A ^d,e   Nakagawa, K ^a  

^a KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b DAIICHI SANKYO CO   (Japan)

^c KYUSHU UNIVERSITY   (Japan)

^d HARVARD MEDICAL SCHOOL   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; ERLOTINIB; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; NEU DIFFERENTIATION FACTOR; PATRITUMAB; PERTUZUMAB; PROTEIN KINASE B; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; ERBB3 PROTEIN, HUMAN; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; NRG1 PROTEIN, HUMAN; SMALL INTERFERING RNA; U3-1287;

A549 CELL LINE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER INHIBITION; CANCER PATIENT; CANCER RESISTANCE; CELL PROLIFERATION; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFICACY; ENZYME ACTIVATION; FEMALE; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOPRECIPITATION; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NON SMALL CELL LUNG CANCER; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; DRUG RESISTANCE; GENETIC TRANSFECTION; LUNG TUMOR; METABOLISM; REAL TIME POLYMERASE CHAIN REACTION; TUMOR CELL LINE; WESTERN BLOTTING; XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; ERLOTINIB HYDROCHLORIDE; FEMALE; HETEROGRAFTS; HUMANS; LUNG NEOPLASMS; MICE; NEUREGULIN-1; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-3; RNA, SMALL INTERFERING; TRANSFECTION;

EID: 84958637800     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2015.142     Document Type: Article

References (37)

1. Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 2005; 5: 341-354.
2. Zhang Q, Park E, Kani K, Landgraf R. Functional isolation of activated and unilaterally phosphorylated heterodimers of ERBB2 and ERBB3 as scaffolds in ligand-dependent signaling. Proc Natl Acad Sci USA 2012; 109: 13237-13242.
3. Jura N, Shan Y, Cao X, Shaw DE, Kuriyan J. Structural analysis of the catalytically inactive kinase domain of the human EGF receptor 3. Proc Natl Acad Sci USA 2009; 106: 21608-21613.
4. Ohsaki Y, Tanno S, Fujita Y, Toyoshima E, Fujiuchi S, Nishigaki Y et al. Epidermal growth factor receptor expression correlates with poor prognosis in non-small cell lung cancer patients with p53 overexpression. Oncol Rep 2000; 7: 603-607.
5. Ji H, Li D, Chen L, Shimamura T, Kobayashi S, McNamara K et al. The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies. Cancer Cell 2006; 9: 485-495.
6. Yi ES, Harclerode D, Gondo M, Stephenson M, Brown RW, Younes M et al. High c-erbB-3 protein expression is associated with shorter survival in advanced nonsmall cell lung carcinomas. Mod Pathol 1997; 10: 142-148.
7. Cappuzzo F, Toschi L, Domenichini I, Bartolini S, Ceresoli GL, Rossi E et al. HER3 genomic gain and sensitivity to gefitinib in advanced non-small-cell lung cancer patients. Br J Cancer 2005; 93: 1334-1340.
8. Shi F, Telesco SE, Liu Y, Radhakrishnan R, Lemmon MA. ErbB3/HER3 intracellular domain is competent to bind ATP and catalyze autophosphorylation. Proc Natl Acad Sci USA 2010; 107: 7692-7697.
9. Engelman JA, Jänne PA, Mermel C, Pearlberg J, Mukohara T, Fleet C et al. ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines. Proc Natl Acad Sci USA 2005; 102: 3788-3793.
10. Zhou B, Peyton M, He B, Liu C, Girard L, Caudler E et al. Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer. Cancer Cell 2006; 10: 39-50.
11. Lee-Hoeflich ST, Crocker L, Yao E, Pham T, Munroe X, Hoeflich KP et al. A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy. Cancer Res 2008; 68: 5878-5887.
12. Baselga J, Swain S. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer 2009; 9:463-475.
13. Schoeberl B, Faber AC, Li D, Liang MC, Crosby K, Onsum M et al. An ErbB3 antibody, MM-121, is active in cancers with ligand-dependent activation. Cancer Res 2010; 70: 2485-2494.
14. Garner A, Bialucha C, Sprague E, Garrett JT, Sheng Q, Li S et al. An antibody that locks HER3 in the inactive conformation inhibits tumor growth driven by HER2 or neuregulin. Cancer Res 2013; 73: 6024-6035.
15. Schaefer G, Haber L, Crocker LM, Shia S, Shao L, Dowbenko D et al. A two-in-one antibody against HER3 and EGFR has superior inhibitory activity compared with monospecific antibodies. Cancer Cell 2011; 20: 472-486.
16. Mirschberger C, Schiller CB, Schräml M, Dimoudis N, Friess T, Gerdes CA et al. RG7116, a therapeutic antibody that binds the inactive HER3 receptor and is optimized for immune effector activation. Cancer Res 2013; 73: 5183-5194.
17. LoRusso P, Jänne PA, Oliveira M, Rizvi N, Malburg L, Keedy V et al. Phase I study of U3-1287, a fully human anti-HER3 monoclonal antibody, in patients with advanced solid tumors. Clin Cancer Res 2013; 19: 3078-3087.
18. Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304: 1497-1500.
19. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350: 2129-2139.
20. Yonesaka K, Zejnullahu K, Lindeman N, Homes AJ, Jackman DM, Zhao F et al. Autocrine production of amphiregulin predicts sensitivity to both gefitinib and cetuximab in EGFR wild-type cancers. Clin Cancer Res 2008; 14: 6963-6973.
21. Kobayashi S, Boggon T, Dayaram T, Jänne PA, Kocher O, Meyerson M et al. EGFR mutation and resistance of non-small cell lung cancer to gefitinib. N Engl J Med 2005; 352: 786-792.
22. Sequist L, Waltman B, Dias-Santagata D, Digumarthy S, Turke AB, Fidias P et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 2011; 3: 75ra26.
23. Noto A, Vitis CD, Roscilli G, Fattore L, Malpicci D, Marra E et al. Combination therapy with anti-ErbB3 monoclonal antibodies and EGFR TKIs potently inhibits non-small cell lung cancer. Oncotarget 2013; 4: 1253-1265.
24. Sergina NV, Rausch M, Wang D, Blair J, Hann B, Shokat KM et al. Escape from HERfamily tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature 2007; 445: 437-441.
25. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007; 316: 1039-1043.
26. Wakui H, Yamamoto N, Nakamichi S, Tamura Y, Nokihara H, Yamada Y et al. Phase 1 and dose-finding study of patritumab (U3-1287), a human monoclonal antibody targeting HER3, in Japanese patients with advanced solid tumors. Cancer Chemother Pharmacol 2014; 73: 511-516.
27. Aguilar Z, Akita R, Finn R, Ramos BL, Pegram MD, Kabbinavar FF et al. Biologic effects of heregulin/neu differentiation factor on normal and malignant human breast and ovarian epithelial cells. Oncogene 1999; 18: 6050-6062.
28. Guerra-Vladusic F, Vladusic E, Tsai M, Lupu R. Signaling molecules implicated in heregulin induction of growth arrest and apoptosis. Oncol Rep 2001; 8: 1203-1214.
29. Yonesaka K, Zejnullahu K, Okamoto I, Satoh T, Cappuzzo F, Souglakos J et al. Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab. Sci Transl Med 2011; 3: 99ra86.
30. Takezawa K, Pirazzoli V, Arcila ME, Nebhan CA, Song X, de Stanchina E et al. HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation. Cancer Discov 2012; 2: 922-933.
31. Ercan D, Zejnullahu K, Yonesaka K, Xiao Y, Capelletti M, Rogers A et al. Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor. Oncogene 2010; 29: 2346-2356.
32. Wilson TR, Lee DY, Berry L, Shames DS, Settleman J. Neuregulin-1-mediated autocrine signaling underlies sensitivity to HER2 kinase inhibitors in a subset of human cancers. Cancer Cell 2011; 20: 158-172.
33. Murakami H, Yamamoto N, Kudo K, Nishio M, Kaneda H, Nakagawa K et al. Phase I study of Patritumab (U3-1287) in combination with erlotinib in Japanese patients with non-small cell lung cancer. Ann Oncol 2013; 24(Suppl 9).
34. Cho BC, Im CK, Park MS, Kim SK, Chang J, Park JP et al. Phase II study of erlotinib in advanced non-small-cell lung cancer after failure of gefitinib. J Clin Oncol 2007; 25: 2528-2533.
35. Von Pawel J, Tseng J, Dediu M, Schumann C, Moritz B, Mendell J et al. Phase 2 HERALD study of patritumab (P) with erlotinib (E) in advanced NSCLC subjects. J Clin Oncol 2014; 32: 5s (abstract 8045).
36. Okabe T, Okamoto I, Tamura K, Terashima M, Yoshida T, Satoh T et al. Differential constitutive activation of the epidermal growth factor receptor in non-small cell lung cancer cells bearing EGFR gene mutation and amplification. Cancer Res 2007; 67: 2046-2053.
37. Takezawa K, Okamoto I, Yonesaka K, Hatashita E, Yamada Y, Fukuoka M et al. Sorafenib inhibits non-small cell lung cancer growth by targeting B-RAF in KRAS wild-type cells and C-RAF in KRAS mutant cells. Cancer Res 2009; 69: 6515-6521.